Today: 7 February 2026
Subscribe
Browse Category

Biotech News News 19 December 2025 - 24 December 2025

Edgewise Therapeutics Stock (EWTX) Jumps on EDG-7500 CIRRUS-HCM Update: Dec. 24, 2025 News, Analyst Forecasts, and Key Catalysts

Edgewise Therapeutics Stock (EWTX) Jumps on EDG-7500 CIRRUS-HCM Update: Dec. 24, 2025 News, Analyst Forecasts, and Key Catalysts

Edgewise Therapeutics, Inc. (NASDAQ: EWTX) stock surged in intraday trading on Wednesday, December 24, 2025, after the company released a fresh update on EDG-7500, its investigational therapy for hypertrophic cardiomyopathy (HCM). By late morning, shares were trading around $26.37—up roughly 21% versus the prior close—after swinging between about $21.30 and $27.05 on the day, with volume above 2.2 million shares. The move follows a company announcement that it has completed Parts B and C of its Phase 2 CIRRUS-HCM trial and reported favorable interim safety observations from Part D—an update that several market outlets characterized as a meaningful de-risking moment
24 December 2025
····
Rezolute, Inc. (RZLT) Stock News and Forecasts on Dec. 24, 2025: Phase 3 sunRIZE Miss, Analyst Target Cuts, and What Comes Next

Rezolute, Inc. (RZLT) Stock News and Forecasts on Dec. 24, 2025: Phase 3 sunRIZE Miss, Analyst Target Cuts, and What Comes Next

Rezolute, Inc. (Nasdaq: RZLT) is still in the spotlight on December 24, 2025, after a brutal mid-December selloff tied to its pivotal clinical trial news—and a wave of follow-on analyst downgrades, price-target resets, and investor-law-firm investigations. As of the latest available pricing around $2.42 per share, the stock is off its post-trial lows but remains dramatically below pre-readout levels, leaving investors weighing a simple question with complicated consequences: was sunRIZE a fatal blow, or a detour that shifts the story toward Rezolute’s next late-stage program? MarketBeat+1 Below is a complete, publication-ready breakdown of the current RZLT stock news, forecasts, and
24 December 2025
·····
BioMarin (BMRN) Stock News Today: Amicus Acquisition Fallout, BMN 349 Cut, and Fresh Wall Street Price Targets (Dec. 22, 2025)

BioMarin (BMRN) Stock News Today: Amicus Acquisition Fallout, BMN 349 Cut, and Fresh Wall Street Price Targets (Dec. 22, 2025)

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is back in the rare-disease spotlight on December 22, 2025, as investors digest a blockbuster acquisition, a quiet pipeline pruning, and a new round of analyst price-target resets. As of 20:24 UTC (3:24 p.m. ET), BioMarin stock traded at about $58.98, down roughly 3.5% on the session, after swinging between $58.75 and $61.44 on heavy volume. That day’s churn isn’t happening in a vacuum. The market is trying to answer one core question: Does BioMarin’s Amicus deal meaningfully “de-risk” growth as Voxzogo heads into a tougher competitive era—without loading the balance sheet too heavily? What
22 December 2025
····
Edgewise Therapeutics (EWTX) Stock News Today: What’s Driving the Volatility, Analyst Forecasts, and Key Catalysts (Dec. 22, 2025)

Edgewise Therapeutics (EWTX) Stock News Today: What’s Driving the Volatility, Analyst Forecasts, and Key Catalysts (Dec. 22, 2025)

December 22, 2025 — Edgewise Therapeutics, Inc. (NASDAQ: EWTX) is back in the spotlight as its stock price whipsaws following a sharp late-week surge and a fresh round of market commentary that mixes optimism about the company’s muscle-disease pipeline with familiar concerns about cash burn in a pre-revenue biotech. As of 18:40 UTC on Dec. 22, EWTX traded at $21.29, after swinging between $27.77 and $21.18 intraday, with volume running well above a million shares. Below is a complete, news-style breakdown of the current coverage and forecasts circulating on Dec. 22, 2025, plus the trial and business milestones investors are
22 December 2025
·····
Cytokinetics (CYTK) Stock Hits 52-Week High as FDA Approval of Myqorzo Triggers Analyst Price-Target Hikes

Cytokinetics (CYTK) Stock Hits 52-Week High as FDA Approval of Myqorzo Triggers Analyst Price-Target Hikes

Cytokinetics, Incorporated (NASDAQ: CYTK) surged on Monday, December 22, 2025, extending a sharp rally that followed the company’s first-ever U.S. drug approval. Shares traded around $69.68 in the session, up roughly 11% from the prior close, after reaching an intraday high near $70.86—a move that pushed the biotech to fresh 52-week highs and re-focused Wall Street on the commercial potential of its newly approved heart drug, Myqorzo (aficamten). Investing.com The immediate catalyst is straightforward: the U.S. Food and Drug Administration approved Myqorzo on December 19, 2025 for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). But the market reaction on December
22 December 2025
·····
Amicus Therapeutics (FOLD) Stock News Today: BioMarin’s $14.50 Buyout, Fresh Analyst Forecasts, and Key Dates to Watch (Dec. 22, 2025)

Amicus Therapeutics (FOLD) Stock News Today: BioMarin’s $14.50 Buyout, Fresh Analyst Forecasts, and Key Dates to Watch (Dec. 22, 2025)

Amicus Therapeutics, Inc. (NASDAQ: FOLD) stock is no longer trading like a typical biotech momentum name—at least not this week. As of December 22, 2025, the stock is hovering around $14.18, tightly anchored to the $14.50 per-share all-cash buyout BioMarin Pharmaceutical has agreed to pay. Investing.com+1 That tight range is the market’s way of saying: “We believe the deal is real, but not free money.” The remaining gap between today’s trading price and the $14.50 cash consideration reflects the time value of waiting, plus the risk (however small) that something delays or disrupts closing. Below is a full, publication-ready breakdown
22 December 2025
······
Vertex Pharmaceuticals (VRTX) Stock News, Forecasts and Analyst Outlook on Dec. 20, 2025: Casgevy Pediatric Data, Kidney Pipeline Momentum, and Journavx Launch Watch

Vertex Pharmaceuticals (VRTX) Stock News, Forecasts and Analyst Outlook on Dec. 20, 2025: Casgevy Pediatric Data, Kidney Pipeline Momentum, and Journavx Launch Watch

December 20, 2025 — Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) heads into the year’s final stretch with investors focused on a familiar question: can the biotech’s next wave of launches and late-stage programs begin to meaningfully diversify a cystic fibrosis (CF) business that has dominated its revenue for more than a decade? VRTX shares most recently closed at $456.20 on Friday, Dec. 19, up 1.97% in that session. StockAnalysis Below is the current news, forecasts, and market analysis shaping Vertex stock as of Dec. 20, 2025, including the latest on Casgevy’s pediatric data, Journavx’s commercial ramp, and a kidney-disease pipeline that
21 December 2025
·····
Biogen Stock (NASDAQ: BIIB) News and Forecasts for Dec. 20, 2025: RBC’s $210 Target, Leqembi Catalysts, and What Investors Are Watching

Biogen Stock (NASDAQ: BIIB) News and Forecasts for Dec. 20, 2025: RBC’s $210 Target, Leqembi Catalysts, and What Investors Are Watching

Biogen Inc. stock (NASDAQ: BIIB) is ending the week on a stronger note after a sharp, high-volume move on Friday’s session—an attention-grabbing setup heading into late December when liquidity often thins and headlines can move shares quickly. As of Saturday, December 20, 2025 (with U.S. markets closed), BIIB is effectively reflecting Friday, Dec. 19’s close of $174.80, up 2.88% on the day. Trading activity stood out: volume hit roughly 15.0 million shares, far above the recent ~1.9 million 50-day average—an unusual spike that often signals institutional participation rather than routine retail churn. MarketWatch+1 Below is a complete, publication-ready breakdown of
20 December 2025
·····
Insmed (INSM) Stock News and Forecasts on Dec. 20, 2025: Brinsupri Trial Miss, Truist Upgrade, and Updated Price Targets

Insmed (INSM) Stock News and Forecasts on Dec. 20, 2025: Brinsupri Trial Miss, Truist Upgrade, and Updated Price Targets

December 20, 2025 — Insmed Incorporated (NASDAQ: INSM) is ending the week in “re-pricing mode” after a mid-stage clinical setback jolted investor expectations, sparked sharp volatility, and triggered a round of analyst price-target revisions. By Friday’s close (the last U.S. trading session before today’s Saturday), Insmed shares finished at $174.84, up about 5% on the day—recovering some ground after Thursday’s steep drop. The catalyst remains the same: Insmed disclosed that its Phase 2b BiRCh study of brensocatib (brand: Brinsupri) in chronic rhinosinusitis without nasal polyps (CRSsNP)missed both primary and secondary efficacy endpoints, prompting the company to discontinue that indication. At
20 December 2025
····
BioMarin (BMRN) Stock Surges on $4.8B Amicus Deal: Latest News, Analyst Forecasts, and What to Watch Next (Dec. 20, 2025)

BioMarin (BMRN) Stock Surges on $4.8B Amicus Deal: Latest News, Analyst Forecasts, and What to Watch Next (Dec. 20, 2025)

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ended Friday’s session sharply higher after announcing a blockbuster rare-disease acquisition that immediately reframed the company’s growth story. Shares closed at $61.15, up about 17.7% on the day, with trading volume far above typical levels—classic “big-news repricing” behavior. Yahoo Finance The catalyst: BioMarin’s agreement to buy Amicus Therapeutics (NASDAQ: FOLD) for $14.50 per share in cash, valuing the deal at approximately $4.8 billion. BioMarin says the acquisition adds two marketed, growing therapies—Galafold (Fabry disease) and Pombiliti + Opfolda (Pompe disease)—plus U.S. rights to DMX-200 (a Phase 3 kidney-disease asset), while also resolving a key piece
20 December 2025
····
Disc Medicine (NASDAQ: IRON) Stock Tumbles on Insider-Selling Headlines as Bitopertin FDA Decision Nears — News, Analyst Forecasts, and What to Watch (Dec. 19, 2025)

Disc Medicine (NASDAQ: IRON) Stock Tumbles on Insider-Selling Headlines as Bitopertin FDA Decision Nears — News, Analyst Forecasts, and What to Watch (Dec. 19, 2025)

Disc Medicine, Inc. stock (NASDAQ: IRON) sank sharply on Friday, Dec. 19, 2025, with IRON down about 10% in late-morning trading and swinging through a wide intraday range that, at one point, dipped into the low $70s before rebounding toward the low $80s. MarketScreener The timing matters: the selloff arrives just weeks before investors expect clarity on Disc’s most important near-term catalyst—an FDA decision on bitopertin for erythropoietic protoporphyria (EPP)—and amid a burst of insider-trading disclosures and Form 144 filings that can spook momentum-driven biotech traders even when sales are planned. MarketBeat+1 Below is a full, up-to-date roundup of what’s
19 December 2025
·····
Insmed Stock (INSM) Rebounds on Dec. 19, 2025 After BiRCh Trial Miss: Latest News, Analyst Forecasts, and What Comes Next

Insmed Stock (INSM) Rebounds on Dec. 19, 2025 After BiRCh Trial Miss: Latest News, Analyst Forecasts, and What Comes Next

December 19, 2025 — Insmed Incorporated (NASDAQ: INSM) is back in focus today after a sharp, news-driven selloff on Thursday and a noticeable bounce on Friday. As of 15:46 UTC on Dec. 19, INSM shares were trading around $174.90, up roughly $8.35 (+5.0%) versus the prior close, with the day’s range spanning about $166.01 to $174.90. That rebound follows a steep Thursday decline after Insmed reported that its Phase 2b BiRCh trial of brensocatib (brand: Brinsupri) in chronic rhinosinusitis without nasal polyps (CRSsNP) missed endpoints, leading the company to discontinue development in that indication. Insmed Incorporated Investor Relations+1 What’s driving
19 December 2025
·····
1 … 5 6 7 8 9 … 12

Stock Market Today

CapitaLand Investment share price jumps as CapitaLand REIT payouts roll in — what’s next for 9CI

CapitaLand Investment share price jumps as CapitaLand REIT payouts roll in — what’s next for 9CI

7 February 2026
CapitaLand Investment shares rose 1.3% to S$3.12 on Friday, bucking a 0.8% drop in Singapore’s benchmark index. CapitaLand Integrated Commercial Trust reported a 16.4% jump in second-half distributable income, while CapitaLand Ascendas REIT posted a 1.4% full-year rise. CapitaLand China Trust saw full-year DPU fall to 4.82 cents amid weaker yuan and occupancy. CLI reports FY2025 results on Feb. 11.
Keppel stock holds near 12-year high after profit jump, special dividend; buyback adds support

Keppel stock holds near 12-year high after profit jump, special dividend; buyback adds support

7 February 2026
Keppel shares closed at S$11.64 on Friday, up 0.17%, after surging 6.1% the previous day on stronger FY2025 profit and a larger dividend plan. The company bought back 151,400 shares for about S$1.74 million. Keppel reported a 29% rise in full-year profit to S$1.02 billion and proposed a total distribution of 47 cents per share, including a special dividend partly paid in Keppel REIT units.
Go toTop